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Abstract
Thyroglobulin (Tg) represents one of the largest known self-antigens involved in autoimmunity. Numerous studies have
implicated it in triggering and perpetuating the autoimmune response in autoimmune thyroid diseases (AITD). Indeed,
traditional models of autoimmune thyroid disease, experimental autoimmune thyroiditis (EAT), are generated by
immunizing mice with thyroglobulin protein in conjunction with an adjuvant, or by high repeated doses of Tg alone,
without adjuvant. These extant models are limited in their experimental flexibility, i.e. the ability to make modifications to
the Tg used in immunizations. In this study, we have immunized mice with a plasmid cDNA encoding the full-length human
Tg (hTG) protein, in order to generate a model of Hashimoto’s thyroiditis which is closer to the human disease and does not
require adjuvants to breakdown tolerance. Human thyroglobulin cDNA was injected and subsequently electroporated into
skeletal muscle using a square wave generator. Following hTg cDNA immunizations, the mice developed both B and T cell
responses to Tg, albeit with no evidence of lymphocytic infiltration of the thyroid. This novel model will afford investigators
the means to test various hypotheses which were unavailable with the previous EAT models, specifically the effects of hTg
sequence variations on the induction of thyroiditis.
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Introduction
Autoimmune conditions targeting the thyroid are a fairly
common occurrence, with a population prevalence of 1–2% [1,2].
Hashimoto’s thyroiditis (HT), the most frequent form of
autoimmune thyroid disease (AITD) is an organ-specific autoim-
mune disease, characterized by the presence of anti-thyroglobulin
(Tg) and anti-thyroid peroxidase (TPO) autoantibodies [3,4],
accompanied by a thyroidal lymphocytic infiltrate which gradually
destroys the gland and, ultimately, results in clinical hypothyroid-
ism [5]. Tg autoantibodies are a hallmark of HT, with high titers
of IgG anti-Tg autoantibodies being found in .90% of HT
patients [6]. The humoral attack mounted against the thyroid in
HT patients is specific and progressive, as it is characterized by the
presence of B cells which show increasing degrees of somatic
hypermutation that produce antibodies with increasing affinities
for Tg [7,8]. Even though ,10% of normal, healthy individuals in
the United States have antibodies to Tg [9], these naturally
occurring autoantibodies differ from those seen in HT patients, as
they are polyreactive [10,11], of lower affinity [12], and are
predominantly IgM in isotype [6]. Overall, the etiology of HT can
be described, broadly, as the interplay between susceptibility genes
and environmental and epigenetic factors [13]. To better
understand the pathoetiology of HT, a number of experimental
systems have been advanced. To date, the ‘gold standard’ model
for Hashimoto’s thyroiditis, murine experimental autoimmune
thyroiditis (EAT), can be induced, in susceptible mice, by
immunization with either autologous or heterologous thyroglob-
ulin, in conjunction with complete Freund’s adjuvant or with
lipopolysaccharide (reviewed in [14]). EAT, like its human disease
counterpart, is characterized by a cellular infiltrate of the thyroid
[15], as well as high titers of anti-Tg autoantibodies [16] and in
vitro splenocyte proliferation, in response to Tg [17]. CD4+ T cells
have been shown to play a pivotal role in disease induction of EAT
[18–23]. Genetic susceptibility to EAT has been shown to occur in
specific strains of mice carrying the MHC alleles H-2s, H-2k, or
H-2q [24] and lies under the control of class II products of the H-
2A [25] region of the murine MHC. We have recently shown that
specific pocket sequences of MHC class II alleles are associated
with susceptibility to EAT [26]. Moreover, the introduction of an
HLA-DRA/DRB1*0301 transgene was sufficient to render a
resistant strain of mouse susceptible to thyroiditis [27].
Despite the knowledge that has been gained by studying EAT and
its special placeinscientifichistory as the firstmodel of experimentally
induced autoimmunity, the method suffers from some limitations.
EAT is not a model that can discriminate between subtle differences
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In fact we have previously shown that specific Tg amino acid variants
confer susceptibility to AITD as well as EAT [28]. Although
spontaneous models of autoimmune thyroiditis exist (e.g. OS (obese
strain) chickens [29], praomys [30], beagles [31], NOD mice [32],
and Buffalo [33] or BB/W [34] rats) that are more pathogenetically
andhistologicallyrelevanttoHTthanEAT,noneofthesemodelshas
proven a practical alternative to EAT. Therefore, there is a current
need for a thyroid autoimmunity model that will be amenable to
testing the contribution to disease made by potential modifiers of hTg
peptide presentation, while allowing breakdown of tolerance without
adjuvants.Inthecurrentmanuscriptwereportthedevelopmentofan
improved model, induced by an hTg cDNA vaccination, in which
‘naked’ Tg plasmid cDNA is introduced into skeletal muscle, and is
presented locally to T-cells resulting in thyroid autoimmunity. Our
new model shows both B and T cell responses against the introduced
hTg antigen, and allows the flexibility of testing hypotheses which
hitherto could not be addressed by the extant model of HT.
Materials and Methods
Thyroglobulin cDNA
Severaloverlapping fragments of the human TG coding sequence
were generated by RT-PCR using proof reading Pfu polymerase
(Invitrogen, Carlsbad, USA). The fragments were joined by overlap
extension PCR or using unique restriction sites in the TG coding
sequence. The final construct was inserted into a pcDNA3.1
plasmid (Invitrogen, Carlsbad, USA) and submitted to direct
sequence analysis. The TG coding sequence contains at least 15
polymorphisms. We chose the human TG sequence reported by
Van de Graaf et al. as a reference sequence and corrected any
deviation from this sequence using site-directed mutagenesis [35].
Preparation of Plasmid DNA
DNA was freshly prepared using the BioRad maxiprep kit.
DNA was ethanol precipitated then resuspended and adjusted to a
concentration of 1.5 mg/ml.
Thyroglobulin protein
Mouse and human thyroglobulin were a gift from the laboratory
of Dr. Terry F. Davies, James J. Peters VA Medical Center.
Mice
C3H/Hen mice were obtained from Taconic laboratories. Mice
which were used were exclusively female and were 8 weeks of age.
All protocols were approved by the Mount Sinai School of
Medicine Institutional Animal Care and Use Committee (animal
use protocol #09-00149).
cDNA Immunization Protocol (without electroporation)
Female C3H/Hen mice were injected with bupivacaine into the
right quadriceps femoris at 2 months of age. Three days after the
induction of muscle injury, mice were immunized with hTg cDNA
(75 mgi n5 0ml of PBS) by injection into the same area which
received the bupivacaine. Subsequently, three boosts (each
administered into the right quadriceps femoris), spaced by approx-
imately one-week intervals, were performed. Animals were
sacrificed 3 weeks after the final boost.
cDNA immunization with electroporation protocol
All electroporation experiments were conducted under anes-
thesia as follows: Mice were anesthetized with Avertin (2,2,2,
tribromoethanol, Sigma-Aldrich T4, 840.2). Avertin was admin-
istered i.p. at a dosage of 0.4–0.6 mg/gram of body weight. After
mice were fully anesthetized, muscle was dissected and exposed.
Following dissection, mice were injected into the specified muscle
group with either 50 ml of 1.5 mg/ml hTg cDNA (a total of 75 mg)
or 50 ml of 1.5 mg/ml of empty vector (total of 75 mg)2pcDNA3.1+
(Invitrogen). DNA was delivered in PBS/1.67% mannitol).
Immediately after injection of Tg cDNA or empty vector, a
current was administered to the site of injection using a square
wave generator. During the exploratory phase of this work
(comparison of electroporation vs. no electroporation) conditions
were 6 pulses total, 60 V/cm, and 50 ms pulse length, with a
200 ms respite between pulses. Later, conditions were changed to
200 V/cm field strength, eight pulses total, and 20 ms per pulse
cycled at 1 Hz (120 ms respite between pulses). These latter
conditions were based on the methodology of Mir et al. [36], who
reported very efficient plasmid DNA transfer in muscle fibers by
using square-wave electric pulses of low field strength (less than
300 V/cm) and of long duration (more than 1 ms). We found that
3–4 cDNA immunizations/electroporations spaced by 1 week
intervals gave the best results. Subsequent boosts were given to
different muscle groups in each immunization as follows: (1) left
quadriceps femoris, (2) right quadriceps femoris, (3) left triceps brachii, and
(4) right triceps brachii. For experiments involving antibody analyses,
blood samples were taken 2–3 weeks after the final boost.
However, for all splenocyte-based assays (i.e. T-cell proliferation
and cytokine assays), animals were sacrificed 2–3 months after the
final boost, in order to study the long-term responses of the
electroporation-based cDNA strategy.
Classical EAT protocol
C3H/HeN mice received 50 ml of human Tg in 100 ml of PBS.
This Tg was administered through a tail vein. 2–3 hours after the
Tg, 20 ml LPS was administered. Three immunizations, spaced by
approximately two week intervals, were administered. Animals
were sacrificed two weeks after the third and final round of
immunization.
Lymphocyte isolation
Spleens were collected from mice and kept on ice in Hanks
Balanced SaltSolution (HBSS). To harvest lymphocytes,thespleens
were placed in complete RPMI medium [RPMI 1640 medium
supplemented with fetal bovine serum (FBS; 10%), L-glutamine
(2 mM) and penicillin-streptomycin (100 U/ml, 100 mg/ml)] (Hy-
clone, Fisher Scientific), and cut in several places. These were then
pressed in a circularmotionwith a plunger from a 6 ml syringe until
only fibrous tissue remained. To further disperse clumps in the
suspension, it was drawn up and expelled several times through a
6 ml syringe using a 19 gauge needle, and then the suspension was
filtered twice through a nylon screen (70 mm cell strainer) into a
50 ml falcon tube. The cell suspension was then spun for
10 minutes at 2006 g and the supernatant was discarded. Cells
wereagainsuspended incompleteRPMImediumandcentrifuged a
second time, and the media were discarded. To remove remaining
non-lymphocytic cells from spleen, 5 ml of ACK lysis buffer was
added to the cells for 5 minutes, after which complete RPMI
medium was added to fill the tube, and centrifuged for 10 minutes.
The remaining cell pellet was washed and resuspended in 10 ml of
complete RPMI medium for counting and plating.
T-cell proliferation assays
Cells isolated from spleens of mice were cultured in RPMI 1640
medium supplemented with fetal bovine serum (FBS; 10%), L-
glutamine (2 mM) and penicillin-streptomycin (100 U/ml,
100 mg/ml) (Hyclone, Fisher Scientific). Cells were plated 2610
5
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treated with either PBS (negative control), thyroglobulin (40 mg/
ml) or concavalin A (2 mg/ml; positive control). After 48 hrs, cells
were pulsed with 1 mCi/well of [
3H]thymidine (MP biomedical,
Costa Mesa, CA). Cells were harvested 18 h later, and
[
3H]thymidine incorporation was measured in a scintillation
counter (TopCount?NXT
TM; PE life sciences, Boston, MA). All
assays were performed in quadruplicates. Data are expressed as
stimulation index. We calculated the stimulation index by using
the following formula: Stimulation index=(CPM of the antigen
treated lymphocytes2background)/(CPM of PBS treated lympho-
cytes2background).
ELISA assay for the detection of thyroglobulin antibodies
10 mg/ml of mouse thyroglobulin in carbonate buffer (pH 9.6)
(total volume 100 ml) was used to coat wells of an ELISA plate, and
incubated overnight at 4uC. The plate was washed 4 times with
PBST (PBS+0.05% tween). 200 ml of blocking buffer (PBST+2.5%
bovine serum albumin) was added to wells and incubated for 1 hour
at 37uC. The plate was then washed 4–6 times with PBST. Sera
weredilutedin1:100inPBST/1%BSAand added ina totalvolume
of 100 ml, in triplicates. Binding was allowed to proceed for 2 hours
at room temperature. Unbound sera were removed by washing 4–6
times with PBST. Then 100 ml of goat anti-mouse IgG-HRP
(Sigma-Aldrich), diluted 1:500 in PBST/1% BSA was added. The
binding was allowed to proceed for 30 minutes at 37uC. Unbound
antibody was removed by washing with PBST 4 times. 100 mlo f
freshly prepared PNPP substrate was added to each well. Readings
were performed by an ELISA reader at 405 nm.
Isotype concentration quantification
In order to test for the isotype of the detected anti-Tg antibodies, a
modified version of the methodology described by Chronopoulou
et al. [37] was employed. In brief, a 10 mg/ml solution of mouse
thyroglobulin in pH 9.6 carbonate buffer was used to coat ELISA
plate wells as described above. The plate was washed 4 times with
PBST (PBS+0.05% Tween). After the final wash, 200 ml of blocking
solution (PBST+2.5% BSA) was added to each well. Blocking was
performed for 1 hour at 37uC. The plate was washed 6 times with
PBST. 100 ml of diluted mouse sera (1:100 in PBST+1% BSA) was
added to eachwell.Incubation proceeded for 1 hr at 37uC. Unbound
sera were removed by washing 10 times with PBST. Next, 100 mlo f
specific anti-mouse IgG subclass conjugated to alkaline phosphatase
(diluted 1:5000 in PBST 1% BSA) were added and incubated at 37uC
for 30 minutes. Subclass specific antibodies could detect mouse IgG1,
IgG2a,a n dI g G 2b (Caltag, catalog # M32108, M32308, M32508).
Excess subclass-specific antibody was removed by washing 10 times
with PBST. For detection of signal, 100 ml of freshly prepared PNPP
substrate (2 tablets/10 ml of 10 mM diethanolamine solution) was
added. Signal was read using an ELISA plate reader at 405 nm.
In order to calculate the amount of a specific IgG subclasses in
the sera, a serum with known amounts of IgG subclasses (MP
Biomedicals catalog #64091) was employed as follows: on the
same plate which was used to read the immunized mouse sera, a
series of wells were coated with anti-mouse IgG (Sigma M6898),
diluted to 50 mg/ml, in the carbonate pH 9.6 buffer and was
added at 100 ml per well. Washing was performed as described
above. The standard reference serum was diluted 1:10 in PBST to
establish a working solution. Next, 7 serial dilutions of reference
serum solution were performed (1:5, 1:25, 1:125, 1:625, 1:3125,
1:15625, and 1:78,125). 100 ml of diluted reference serum was
added to the wells coated with anti-mouse IgG. These reference
dilutions were performed in triplicate to construct the calibration
curve. Standard curves typically gave an R
2$0.95.
Cytokine ELISAs
Interferon gamma and interleukin 4 levels in the supernatant of
stimulated lymphocytes were determined by a commercial ELISA
kits (BD Biosciences, OptEIA
TM).
Statistical Analyses
The differences between T cell proliferation indexes and
antibody levels at different conditions were analyzed using
Student’s t-test. P-values of ,0.05 were considered significant.
Results
Electroporation increases autoimmune responses to Tg
Despite the immense potential of skeletal muscle to uptake and
express a multitude of plasmid cDNAs [38], the inherent
inefficiency of this process results in low levels of target gene
expression and immune responses [39,40]. Hence, a number of
methodologies have been advanced to increase the efficiency of
cDNA uptake. Muscle regeneration, induced by treatment with
cardiotoxin or bupivacaine, prior to cDNA immunizations, has
been shown to increase target gene expression by up to 80-fold [41].
Similarly, electroporation of skeletal muscle immediately after the
injection of cDNA has been demonstrated to result in a significant
improvement in transfection efficiency [42]. In order to assess the
effects of different potential modes of hTg cDNA immunization
delivery, we employed two approaches, one direct, and the other
facilitated by electroporation. We injected, in 3 rounds, hTg plasmid
into the muscles of 8-week old female C3H/HeN mice that had
been previously treated with bupivacaine, and compared the
resultant anti-Tg antibody responses to those of mice that received
hTg immunization in conjunction with electroporation. Mouse sera
were analyzed for the presence of anti-murine Tg IgG. Comparison
of sera from the two groups of mice showed that electroporation-
facilitated cDNA delivery significantly increased the levels of Tg
reactive antibodies (Figure 1) compared to direct delivery in
regenerating muscle. In view of these initial results all subsequent
experiments were performed with electroporation.
hTg cDNA immunization and electroporation induces
T-cell proliferative responses to Tg
Splenocytes isolated from hTg injected and electroporated
C3H/HeN female mice proliferated in response to hTg. Spleno-
cytes from electroporated mice showed significantly increased
proliferation, compared to similarly treated splenocytes from non-
immunized mice (Figure 2).
A potential Th1 bias of the T-cell response in hTg
immunized/electroporated mice
To determine if cDNA immunization with hTG resulted in a
Th1 or Th2 polarization of the anti-Tg response we further
characterized the T cell responses by examining cytokine
production. IFN-gamma production was significantly increased
in response to hTg cDNA (Figure 3), while IL-4 was below the
limits of detection (data not shown). Hence, the anti-hTg immune
response in our mice is suggestive of a Th1 bias, but does not rule
out involvement of the TH17 pathway.
Analysis of the antibody response to cDNA
immunization/electroporation with hTg
All the mice that were immunized with hTg cDNA and
electroporated developed a robust antibody response to mouse
thyroglobulin (mTg) demonstrating the development of a de novo
thyroid autoimmunity. Analysis of the IgG subtype elicited by
Thyroglobulin cDNA Immunization New Disease Model
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of the Th1 predominance of the immune response to Tg observed
by the cytokine profile. IgG2a showed the highest levels among the
anti-hTg IgG subtypes, suggesting a Th1 bias of the autoimmune
response (Figure 4).
Induction of the classical EAT model
In order to compare our new model to the classical EAT model,
we also induced classical EAT in the mice by immunizing them i.v.
with hTg protein followed by i.v. LPS 2–3 hrs later. As expected,
we saw a robust anti-Tg antibody response. Intriguingly, the
classical EAT model showed a different IgG subtype response than
the cDNA immunized/electroporated mice. While IgG2a showed
high levels in the classical EAT similar to the cDNA immunization
model, IgG2b showed very high levels in the classical EAT, while
its levels remained very low in the cDNA immunized mice
(Figure 5).
Thyroid Histology
Hematoxylin-eosin staining of thin sections from thyroid glands
of mice from the different experiments did not show any evidence
of lymphocytic infiltration into the thyroid gland (data not shown).
Discussion
Several cDNA vaccine-based animal models have been recently
developed, the most notable of which is experimental autoimmune
Graves’ disease (EAGD), induced by immunization of BALB/c
mice with an Adenovirus vector carrying the TSH receptor [43].
The main advantage of cDNA immunization based mouse models
is that they are easily amenable to genetic manipulations of the
cDNA immunogen. For example, in the case of EAGD, it was
found that immunization with the alpha subunit of the TSHR
alone gave a stronger immune response and more severe disease
phenotype than when using the full-length TSHR [44,45].
Moreover, since the auto-antigen is presented in the correct
conformation during cDNA immunization (as it is produced and
expressed on muscle cells) the immune response generated by
cDNA immunization is more relevant to the human version of
disease.
Up until 1980, it was believed that Tg reactive T-cells were
completely deleted by central tolerance mechanisms. Therefore,
the dogma was that EAT can only be induced with adjuvant which
stimulated non-Tg reactive T-cells to bypass the tolerance to Tg
and provide help for Tg-reactive B-cells. However, in 1980–1981,
Rose and colleagues published seminal studies clearly demon-
strating that repeated immunizations with high doses of Tg
without adjuvant could induce a strong anti-Tg antibody response
and lymphocytic infiltration of the thyroid [46,47]. These studies
Figure 1. Effects of different means of cDNA delivery on anti-
Tg antibody response. Shown is an ELISA measuring total IgG (all
subclasses), directed against murine thyroglobulin (Tg). The results
demonstrate a significant anti-Tg response in mice immunized with hTg
cDNA. For this analysis, we compared 2 non-immunized mice, the 2
best responders, out of a group of 6 that were immunized with hTg
without electroporation, and 6 hTg cDNA immunized/electroporated
mice. Relative to directly immunized mice, the use of an electric current
(6 pulses total, 60 V/cm, and 50 ms pulse length, with a 200 ms respite
between pulses) caused a significant increase in the level of anti-Tg
antibodies (p=0.037). All readings were performed in triplicate. Data
are shown as mean + standard error of the mean (SEM). Animals
immunized with empty vector (pCDNA3.1+) exhibited no response
(data not shown) to mouse Tg.
doi:10.1371/journal.pone.0019200.g001
Figure 2. T cell stimulation. Splenocytes isolated from immunized (2–3 months after the final boost) and non-immunized C3H/HeNmice were
incubated with increasing concentrations of hTg protein for 72 hrs. Splenocytes from hTg immunized/electroporated mice showed significantly
increased proliferation, compared to similarly challenged splenocytes from non-immunized mice. The x axis represents the concentration (mg/ml) of
hTg which was used to stimulate the splenocytes. All T-cell proliferation experiments were performed in triplicates. Data, which were initially
recorded as cpm, were subsequently expressed relative to splenocytes which did not receive thyroglobulin, are shown as mean + SEM.
doi:10.1371/journal.pone.0019200.g002
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do escape central tolerance. Moreover, the authors correctly
predicted the existence of peripheral regulatory mechanisms for
these auto-reactive T-cells that escaped tolerance. Indeed,
McLachlan et al. have recently shown that depletion of Tregs by
itself is enough to cause anti-Tg and anti-TPO antibody response
and massive lymphocytic infiltration of the thyroid when mice
were immunized with TSHR cDNA with no adjuvant [48,49].
Along a similar vein of thought, our manuscript also supports the
hypothesis that anti-Tg reactive T-cells escape central tolerance,
since our model shows the induction of an immune response
without the addition of adjuvant.
Traditionally, cDNA vaccines are best known as agents that can
generate protective immunity against infectious disease and
experimental cancer, or can supply a therapeutic dose of a gene
product (reviewed in [39]). However, the same principles which
allow DNA vaccination to produce a prolonged, endogenous
expression of antigen [50], along with the generation of long-term
humoral and cellular immune responses [51–53], could be utilized
to promote and sustain an immune response against a self-antigen,
Figure 3. Th1 nature of the Cytokine Profile. Splenocytes were isolated from immunized/electroporated (2–3 months after the final boost) and
non-immunized mice. 2610
5 cells were challenged with 0, 5, or 20 mg/ml of human thyroglobulin. Supernatants were collected and were analyzed for
the presence of cytokines. hTg-treated splenocytes from immunized/electroporated animals secreted significantly higher levels of interferon-gamma
than controls. Mice immunized with empty vector showed no differences compared to the non-immunized controls (data not shown). All readings
were performed in triplicate. Data are shown as mean + SEM.
doi:10.1371/journal.pone.0019200.g003
Figure 4. IgG subtypes or anti-mTg antibodies produced by hTg immunized/electroporated mice. Three, 8-week old C3H/HeN mice
received hTg immunization/electroporation while 4 mice received an empty pcDNA plasmid electroporation (denoted by ‘**’). Anti-mouse Tg
antibodies of the IgG2a subclass were the most prevalent isotype, followed by IgG1. There were very low levels of anti-mTg antibodies of the IgG2b
class. All ELISA experiments were performed in triplicates. Data are presented as mean + SEM.
doi:10.1371/journal.pone.0019200.g004
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the immunostimulatory nature of the plasmid DNA itself, due to
CpG motifs, directs the de novo synthesis of MHC II molecules
and chemokines (e.g. monocyte chemotactic protein-1), allowing
the myocyte to become an active participant in the development of
an immune response by presenting the autoantigen. Indeed, in
terms of breaking peripheral tolerance to the thyroid, cDNA-based
vaccines have actually proven to be more accurate disease models
than traditional protein/adjuvant-based autoimmune models. For
example, the administration of TPO in a plasmid format, resulted
in high affinity antibodies with limited epitopic recognition, similar
to the TPO antibodies produced in HT patients [54]. Subsequent
manipulation of this protocol produced lymphocytic infiltration in
DR3+ MHCII-null/NOD mice, creating an even more accurate
model of disease [55]. Finally, the EAGD model, in which TSHR
cDNA is administered in an adenoviral vector, produces TSHR
stimulating antibodies and hyperthyroidism [43]. Hence, we
anticipated that an optimized HT cDNA model, using thyroglob-
ulin cDNA expressed in the microenvironment of the mouse
myocyte, will be sufficient to initiate an immune response to Tg.
Thyroglobulin is a 660 kDA homodimeric, iodinated glycopro-
tein that serves as a precursor for thyroid hormones [15], and
represents a remarkable 75%–80% of total thyroidal protein [56].
Two whole genome linkage screens have shown strong evidence of
linkage of HT with the Tg locus on 8q24 [57,58]. Furthermore,
case-control and family-based association studies, using microsat-
ellites in introns 10 and 27 of the Tg gene demonstrated
association of the Tg gene with HT [59]. Hence, it is likely that
Tg is the primary antigen in HT precipitating the disease, even
though anti-TPO antibodies are the most specific antibodies for
clinical diagnosis. Indeed, recent data support the notion that Tg is
the primary antigen precipitating AITD and breaking tolerance
[60,61]. Therefore, selecting Tg for cDNA immunization was a
logical choice, in order to precipitate a break in tolerance to the
thyroid. Our study demonstrated that electroporation in addition
to hTg cDNA immunization significantly increased the immune
response elicited by Tg. Electroporation consists of applying an
electric potential, usually in the form of a square wave [62], to an
area of muscle that has been vaccinated with cDNA, and has been
advanced as a means to ensure that foreign DNA is taken up more
efficiently and expressed for longer durations [63–65].
The current new model we have developed demonstrates that it
is possible to breakdown tolerance to Tg, using cDNA immuni-
zation coupled with electroporation. However, despite the
breakdown in tolerance, the mice did not develop lymphocytic
infiltration of the thyroid and hypothyroidism. One potential
explanation for the lack of lymphocytic infiltration of the thyroid is
that we have immunized with human Tg. Even though there is
70% amino acid sequence identity between human and mouse Tg,
enough differences may exist that it may not be sufficient, using
hTg cDNA in mice, to induce a response to mouse Tg coupled with
infiltration of the thyroid. A similar situation is seen in the cDNA
immunization-based model of Graves disease (EAGD). In the
EAGD model, which uses cDNA immunization with human
TSHR to induce Graves’ disease, a significant T-cell and antibody
response is observed to human TSHR, and the antibodies,
through cross-reaction with the mouse TSHR, stimulate the
mouse TSHR causing thyrotoxicosis. Nevertheless, there is no T-
cell infiltration of the thyroid [43]. Attempts to induce EAGD with
mouse TSHR resulted in no autoimmune response at all. The
suggested reason for the inability to breakdown tolerance when
immunizing with mouse TSHR was that these mice have inborn
central tolerance to mouse self-antigens including mouse TSHR
[66]. It is possible that a similar phenomenon would be observed
in our model, if one tried to induce EAT by immunization with
mouse Tg cDNA.
Despite the lack of lymphocytic infiltration of the thyroid, our
findings furnish significant implications and afford new options to
future studies focusing on the etiology of AITD. The main
advantage of our model is that it enables immunization with
human Tg and it facilitates manipulating the sequence of the hTg
cDNA (through site directed mutagenesis), in order to investigate
the importance of different parts of the molecule in inducing
autoimmunity. Indeed, our genetic studies have demonstrated a
strong association between amino acid variants in the thyroglob-
ulin gene and AITD, suggesting that subtle sequence changes in
hTg may have a significant effect on disease susceptibility [28].
These findings were in agreement with older studies by Rose and
colleagues that have demonstrated that the source of Tg used to
induce EAT determined the severity of disease [67]. Our novel
mouse model offers the first opportunity to test the effects of the
human Tg sequence on the induction of thyroid autoimmunity in
mice in vivo. The thyroglobulin used in our cDNA immunizations
was able to breakdown tolerance even though it was not iodinated,
since it was produced in muscle cells that lack the different
enzymes and transporters required for iodination of Tg. These
data support the notion that iodination of Tg may not be essential
for its immunoreactivity. However, it is possible that the lack of
iodination was the cause of lack of lymphocytic infiltration of the
thyroid. If this is the case, it would imply that iodination is not
required for Tg peptide presentation and stimulation of a T-cell
and B-cell response to Tg. However, iodination of Tg may be
required for stimulation of cytotoxic T-cell stimulation (through
MHC class I) leading to infiltration of the thyroid gland.
In summary, for the first time we have produced a mouse model
of thyroid autoimmunity using cDNA immunization, coupled with
electroporation, without the need for a strong adjuvant such as
CFA or LPS. Our novel mouse model is unique because it involves
immunization by intramuscular injection of Tg cDNA resulting in
production of non-iodinated Tg in muscle cells. Because we
utilized cDNA immunization our model is amenable to genetic
modification of Tg used in the immunization. This model should
prove useful for future studies on the role of different Tg sequence
Figure 5. IgG subtypes or anti-mTg antibodies produced by
C3H/HeN mice induced with classical EAT by immunizing with
hTg protein and adjuvant. Three, 8-week old C3H/HeN mice were
intravenously immunized with 50 mg of hTg in 100 ml of PBS into the tail
vein. 2–3 hours later, 20 ml of LPS was injected into the tail vein. Three
immunizations, spaced two weeks apart, were administered. Animals
were sacrificed two weeks after the third and final round of
immunization. At sacrifice, sera were collected and were analyzed for
the presence of anti-mTg and the specific isotype of the antibodies. All
ELISA experiments were performed in triplicates. Data are shown as
mean + SEM.
doi:10.1371/journal.pone.0019200.g005
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Furthermore, the milieu afforded by the mouse myocyte will allow
testing, through the co-immunization and electroporation of their
respective cDNA’s, of the role of pro-inflammatory and pro-
apoptotic factors in the pathoetiology of Hashimoto thyroiditis.
Overall, this new model of thyroid autoimmunity is a model with
much potential and flexibility.
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